4.8 Letter

Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade

Related references

Note: Only part of the references are listed.
Article Oncology

Distinct Mechanisms of Mismatch-Repair Defi ciency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow et al.

Summary: This study found that patients with mutational MMRd endometrial cancer had higher response rates and longer survival after treatment with the PD-1 inhibitor pembrolizumab compared to those with epigenetic MMRd. However, mutation burden did not correlate with immune checkpoint blockade response. The study also revealed different modes of antitumor immunity between mutational and epigenetic MMRd cancers.

CANCER DISCOVERY (2023)

Article Immunology

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Juan Dubrot et al.

Summary: This study uses genome-scale in vivo CRISPR screens to uncover the mechanisms of immune evasion in tumors and the role of immune inhibitory checkpoints. The research finds that loss of tumor interferon signaling increases sensitivity to immunity, while upregulation of classical and non-classical MHC class I inhibitory checkpoints facilitates immune escape.

NATURE IMMUNOLOGY (2022)

Article Multidisciplinary Sciences

Disease variant prediction with deep generative models of evolutionary data

Jonathan Frazer et al.

Summary: Quantifying the pathogenicity of protein variants in human disease-related genes is important for clinical decisions, but most variants still have unknown consequences. Current computational methods rely on training machine learning models on known disease labels, resulting in unreliable models due to sparse and biased labels.

NATURE (2021)

Article Multidisciplinary Sciences

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

Jason B. Williams et al.

NATURE COMMUNICATIONS (2020)